Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
Product Description
Yuxi Walvax Biotechnology Co., Ltd.
-
CN -
2023On CPHI since
-
1000 - 4999Employees
Company types
Categories
Yuxi Walvax Biotechnology Co., Ltd.
-
CN
-
2023On CPHI since
-
1000 - 4999Employees
Company types
More Products from Yuxi Walvax Biotechnology Co., Ltd. (2)
-
Product 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
To prevent invasive diseases caused by 13 serotypes of Streptococcus pneumoniae in infants and children 6 weeks through 5 years of age (before the 6th birthday) -
Product 23-valent Pneumococcal Polysaccharide Vaccine
To prevent invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance